299 related articles for article (PubMed ID: 25613607)
1. [Chemical modification endows heparin with low anticoagulant and high antineoplastic activities].
Liang Y; Li LB; Zhang P; Wu CZ; Zhao SR; Zhang QW; Liu H; Jiang ZW
Nan Fang Yi Ke Da Xue Xue Bao; 2015 Jan; 35(1):40-6. PubMed ID: 25613607
[TBL] [Abstract][Full Text] [Related]
2. Acetylation may strengthen the antitumor activity of low molecular heparin.
Liang Y; Wang Y; Wang G; Wang A; Wang K; Duan G
Transl Cancer Res; 2021 Jan; 10(1):461-468. PubMed ID: 35116275
[TBL] [Abstract][Full Text] [Related]
3. [Anticoagulant activity of low-molecular-weight heparins obtained using a hydrolase complex].
Drozd NN; Tolstenkov AS; Bannikova GE; Miftakhova NT; Lapikova ES; Makarov VA; Varlamov VP
Eksp Klin Farmakol; 2007; 70(6):19-24. PubMed ID: 18318190
[TBL] [Abstract][Full Text] [Related]
4. Neutralisation of the anti-coagulant effects of heparin by histones in blood plasma and purified systems.
Longstaff C; Hogwood J; Gray E; Komorowicz E; Varjú I; Varga Z; Kolev K
Thromb Haemost; 2016 Mar; 115(3):591-9. PubMed ID: 26632486
[TBL] [Abstract][Full Text] [Related]
5. In vitro comparison of dabigatran, unfractionated heparin, and low-molecular-weight heparin in preventing thrombus formation on mechanical heart valves.
Maegdefessel L; Linde T; Krapiec F; Hamilton K; Steinseifer U; van Ryn J; Raaz U; Buerke M; Werdan K; Schlitt A
Thromb Res; 2010 Sep; 126(3):e196-200. PubMed ID: 20659761
[TBL] [Abstract][Full Text] [Related]
6. High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives.
Park JW; Jeon OC; Kim SK; Al-Hilal TA; Jin SJ; Moon HT; Yang VC; Kim SY; Byun Y
J Control Release; 2010 Dec; 148(3):317-26. PubMed ID: 20869408
[TBL] [Abstract][Full Text] [Related]
7. Ultrasonic-assisted preparation of a low molecular weight heparin (LMWH) with anticoagulant activity.
Achour O; Bridiau N; Godhbani A; Le Joubioux F; Bordenave Juchereau S; Sannier F; Piot JM; Fruitier Arnaudin I; Maugard T
Carbohydr Polym; 2013 Sep; 97(2):684-9. PubMed ID: 23911501
[TBL] [Abstract][Full Text] [Related]
8. Antithrombotic and anticoagulant activity of depolymerized fragment of the glycosaminoglycan extracted from Stichopus japonicus Selenka.
Suzuki N; Kitazato K; Takamatsu J; Saito H
Thromb Haemost; 1991 Apr; 65(4):369-73. PubMed ID: 1647552
[TBL] [Abstract][Full Text] [Related]
9. The effects of unfractionated heparin, low molecular weight heparin and danaparoid on the thromboelastogram (TEG): an in-vitro comparison of standard and heparinase-modified TEGs with conventional coagulation assays.
Coppell JA; Thalheimer U; Zambruni A; Triantos CK; Riddell AF; Burroughs AK; Perry DJ
Blood Coagul Fibrinolysis; 2006 Mar; 17(2):97-104. PubMed ID: 16479191
[TBL] [Abstract][Full Text] [Related]
10. Anticoagulant mechanisms of covalent antithrombin-heparin investigated by thrombelastography. Comparison with unfractionated heparin and low-molecular-weight heparin.
Atkinson HM; Mewhort-Buist TA; Berry LR; Chan AK
Thromb Haemost; 2009 Jul; 102(1):62-8. PubMed ID: 19572069
[TBL] [Abstract][Full Text] [Related]
11. Heparin and low molecular weight heparin in thrombosis and beyond.
Mousa SA
Curr Opin Investig Drugs; 2002 Aug; 3(8):1181-6. PubMed ID: 12211411
[TBL] [Abstract][Full Text] [Related]
12. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low-molecular-weight heparin, and fondaparinux in different clinical settings.
Greinacher A; Alban S; Omer-Adam MA; Weitschies W; Warkentin TE
Thromb Res; 2008; 122(2):211-20. PubMed ID: 18262226
[TBL] [Abstract][Full Text] [Related]
13. Heparin and low-molecular-weight heparin.
Gray E; Mulloy B; Barrowcliffe TW
Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
[TBL] [Abstract][Full Text] [Related]
14. Properties of Heparinoids Premixed with Tumor-Derived Extracellular Vesicles.
Manandhar S; Park J; Kothandan VK; Lee J; Alam F; Jee JP; Hwang J; Byun Y; Hwang SR
Bioconjug Chem; 2018 Nov; 29(11):3757-3767. PubMed ID: 30372043
[TBL] [Abstract][Full Text] [Related]
15. Conjugation of low-molecular-weight heparin and deoxycholic acid for the development of a new oral anticoagulant agent.
Lee Y; Nam JH; Shin HC; Byun Y
Circulation; 2001 Dec; 104(25):3116-20. PubMed ID: 11748110
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of low-molecular-weight heparin reversal by platelet factor 4.
Fiore MM; Mackie IM
Thromb Res; 2009 May; 124(1):149-55. PubMed ID: 19195682
[TBL] [Abstract][Full Text] [Related]
17. Low-molecular weight molluscan glycosaminoglycan from bivalve Katelysia opima (Gmelin).
Vijayabaskar P; Balasubramanian T; Somasundaram ST
Methods Find Exp Clin Pharmacol; 2008 Apr; 30(3):175-80. PubMed ID: 18597000
[TBL] [Abstract][Full Text] [Related]
18. The anticoagulant capacity of plasmatic unfractionated heparin decreases at 23 degrees C.
Stief TW
Blood Coagul Fibrinolysis; 2007 Mar; 18(2):209-12. PubMed ID: 17287642
[TBL] [Abstract][Full Text] [Related]
19. Preparation of low molecular weight heparin using an ultrasound-assisted Fenton-system.
Zhi Z; Li J; Chen J; Li S; Cheng H; Liu D; Ye X; Linhardt RJ; Chen S
Ultrason Sonochem; 2019 Apr; 52():184-192. PubMed ID: 30559077
[TBL] [Abstract][Full Text] [Related]
20. Fibrinolytic and anticoagulant activity after a single subcutaneous administration of a low dose of heparin or a low molecular weight heparin-dihydroergotamine combination.
Grimaudo V; Omri A; Kruithof EK; Hauert J; Bachmann F
Thromb Haemost; 1988 Jun; 59(3):388-91. PubMed ID: 2847348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
